III Capital Management’s European Biotech Acquisition Corp. Units EBACU Stock Holding History

III Capital Management’s Portfolio EBACU Stock Details EBACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-7,496	Closed	-$74K	–	179
2021 Q4	$74K	Sell	7,496 -22,504	-75%	-$223K	0.01%	144
2021 Q3	$298K	Hold	30,000	–	–	0.02%	118
2021 Q2	$299K	Hold	30,000	–	–	0.02%	99
2021 Q1	$301K	Buy	+30,000	New	+$300K	0.04%	83

Other funds holding EBACU

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

SMA

Sage Mountain Advisors Atlanta, Georgia $1.43B AUM 16.47% 1-Year Est. Return

MTCM

Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return

Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

III Capital Management's EBACU Position: Q1 2022 in Review

III Capital Management sold out of European Biotech Acquisition Corp. Units (EBACU) in Q1 2022, closing a stake of 7,496 shares — an estimated $74K sold.

III Capital Management first reported a position in EBACU in Q1 2021 and held it in 4 quarters. The position peaked at $301K in Q1 2021. 22 funds tracked by Wall St. Rank hold EBACU as of Q1 2022.

III Capital Management reported no remaining European Biotech Acquisition Corp. Units position as of Q1 2022 after selling out during the quarter.
III Capital Management sold 7,496 European Biotech Acquisition Corp. Units shares in Q1 2022, an estimated $74K.
III Capital Management first reported a position in European Biotech Acquisition Corp. Units in Q1 2021 and held it in 4 quarters.
III Capital Management's European Biotech Acquisition Corp. Units position peaked at $301K in Q1 2021.
22 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Units as of Q1 2022.

Based on III Capital Management's 13F filing for Q1 2022, filed 16 May 2022.